Table 5.
Risk of osteoporotic fracture in current TZD users compared with other AD drug users, by number of TZD prescriptions
| Fracture, n | Age-/sex-adj. HR (95 % CI) | Fully adj. HR (95 % CI)a | |
|---|---|---|---|
| No TZD use | 13,873 | ||
| Current TZD use | 116 | 0.98 (0.81–1.18) | 1.07 (0.89–1.29) |
| By number of TZD prescriptions ever before | |||
| 1–4 | 27 | 0.80 (0.55–1.17) | 0.87 (0.59–1.26) |
| 5–8 | 17 | 0.70 (0.44–1.13) | 0.76 (0.47–1.23) |
| 9–14 | 20 | 0.80 (0.52–1.24) | 0.88 (0.57–1.37) |
| 15–29 | 28 | 1.05 (0.72–1.52) | 1.16 (0.80–1.68) |
| ≥30 | 24 | 2.70 (1.81–4.02) | 3.03 (2.03–4.52)b |
TZD thiazolidinedione, AD antidiabetic, adj adjusted, HR hazard ratio, CI confidence interval
aAdjusted for age; gender; use of statins, antidepressants, or opioids in the previous 6 months; history of fracture; and cerebrovascular disease
bStatistically significant difference (p < 0.05) between current TZD users with ≥30 TZD prescriptions ever before and all of the other categories, based on Wald test